Interestingly, in recent studies, ghrelin has been shown to exert antifibrotic effects in the injured liver, which raises the question of whether blockade of GHSR accelerates liver fibrosis, a liver disease commonly seen in patients with metabolic syndrome, obesity, and diabetes.[17, 18, 19, 20, 21] Interestingly, our current study revealed a profibrotic effect of macrophage GHSR in chronic liver injury. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.